Drug intelligence / Profile preview

B3-IL2

Development stage: Preclinical
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intraperitoneal

Overview

B3-IL2 is an experimental **interleukin-2-based immunocytokine** consisting of an IL-2 cytokine fused to an antibody fragment that specifically targets **PD-L1 (programmed death-ligand 1)**. It has been studied in preclinical models as a therapy to direct cytokine activity toward the tumor microenvironment, aiming to enhance local immune activation against cancer. In mice, B3-IL2 significantly reduced tumor growth in orthotopic pancreatic carcinoma and, in combination with the monoclonal antibody TA99, slowed melanoma progression and prolonged survival.

Targets

IL2RB (IL-2 receptor beta chain)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on B3-IL2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B3-IL2.

Explore the full profile